Mylan Insists Complex Generics Strategy Is Poised To Deliver
With one high-profile approval in its pocket – a version of Teva's blockbuster Copaxone – Mylan's management believes its strategy of investing in complex generics and biosimilars will help the company navigate challenges in the US generic market.
You may also be interested in...
Teva CEO Schultz Walks Smack Into A Rough Financial Situation
Teva announced lower third quarter sales, said it would miss it's 2017 profit forecasts and acknowledged looming debt challenges. It was only CEO Kare Schultz's second day on the job.
Generic Price-Fixing Lawsuit Grows As More Companies, Two Executives Named Defendants
US state attorneys general name executives from Mylan and Emcure as defendants, and list may further expand as investigation continues into additional companies and drugs.
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
FDA issued a complete response letter for Mylan's application for a biosimilar version of Amgen's Neulasta. However, Mylan said the CRL does not change its US launch expectations, targeted for late 2018 or early 2019.